Have you ever wondered why two people can respond differently to the same medicine? Age, other treatments, kidney and liver function, adherence and underlying illness all matter. In certain cases, inherited genetic differences also affect how a drug is processed or how well it works. Pharmacogenetic testing investigates some of those differences.
The science is promising, but it has limits. A commercial pharmacogenomics test does not tell you the perfect medicine for every condition, nor does it replace a prescription review. Here is how to judge when DNA information may be useful — and when a simpler clinical conversation matters more.
What is pharmacogenetics?
Pharmacogenetics studies how particular genetic variants influence responses to medicines. A laboratory might analyse genes involved in drug-metabolising enzymes, transport proteins or drug targets. The results can sometimes help a clinician anticipate an unusually slow or fast metabolism, altered effectiveness or a higher risk of a specific adverse reaction.
The term pharmacogenomics is often used for a broader approach involving multiple genes or the genome. In everyday healthcare discussions the two expressions frequently overlap.
Genetic tests generally involve a cheek swab or saliva sample, although the collection method depends on the provider. Your DNA sequence is largely stable across life, so a relevant inherited result will not normally need repeating every few months. The evidence connecting a result to a treatment decision can, however, change over time.
A real example: CYP2C19 and clopidogrel
Clopidogrel is an antiplatelet drug that must be activated by enzymes in the body. One of the important enzymes is produced under the influence of the CYP2C19 gene. Some inherited versions of CYP2C19 reduce enzyme activity, making clopidogrel less effective for certain people.
NICE has evaluated CYP2C19 testing following ischaemic stroke or transient ischaemic attack. This is a concrete example of a gene–medicine relationship with a defined clinical use, rather than a generic promise that 'your DNA reveals the best drugs'. Whether testing is appropriate depends on the patient's diagnosis and treatment pathway.
Other clinically relevant gene–drug relationships exist, but they are not interchangeable. Evidence may be stronger for some medicines, weaker for others and completely absent for many drugs.
What might a pharmacogenetic report contain?
Depending on the panel, a report may list gene variants and predicted enzyme activity classifications, such as poor, intermediate, normal, rapid or ultrarapid metabolism. Some reports link these findings to selected medicines and prescribing recommendations. Others contain broader wellness associations with much less established clinical utility.
A good report should specify which genes and variants were tested, the laboratory method, its limitations and the evidence supporting each medication association. The presence of a gene name alone is not proof that a medicine will be unsafe or ineffective.
What genetic testing cannot predict
Many factors influence treatment outcomes beyond DNA. A normal predicted metaboliser can still experience side effects. Someone classified as a poor metaboliser for one enzyme may respond perfectly well to a medicine that does not rely on that enzyme. Multiple medicines can also alter enzyme activity in ways that a DNA result cannot fully predict.
A DNA medication test cannot guarantee that antidepressants, pain medicines, blood thinners or other prescribed drugs will work for you. It also cannot diagnose a medication allergy, determine the correct dose for every drug or overrule clinical judgement. Claims of universal 'personalised prescribing' should be treated cautiously.
Who might benefit from targeted testing?
The strongest reason is a specific prescribing decision where recognised guidance supports testing for a particular gene–drug pair. A clinician may also review pharmacogenetic results when someone has had an unexpected response or when a medicine under consideration has an established genetic association.
For a person with multiple medicines or complicated symptoms, a medication review may reveal interactions, dosing issues or other explanations without requiring genetic testing. A targeted gene test may be more helpful than an extensive panel if the clinical question is narrow.
What to ask before buying a test
Before ordering, ask:
- Which exact genes and variants does the panel analyse?
- Which medicines have strong, clinically actionable evidence?
- Will the report describe limitations and avoid overclaiming?
- Who will interpret the results in the context of my prescription?
- How will sensitive genetic information be stored, accessed and shared?
- Will any reported finding be suitable for use by my NHS or private prescriber?
Do not change or stop a prescribed medicine based on a consumer report without advice from the prescribing clinician. In some cases changes are urgent; in others, the report may have little practical relevance.
Is pharmacogenetic testing the same as genetic disease screening?
No. Pharmacogenetics looks at gene variants in relation to medication response. It does not serve as a broad diagnostic test for inherited disease, cancer risk or general nutritional needs. Even when the same genetic technology is used, the clinical question and interpretation framework are different.
For some pharmacogenetic markers, your result may also have relevance to relatives, but that does not mean everyone in the family should order the same commercial panel. Discuss any broader implications with an appropriate genetics specialist.
Pharmacogenetic testing in London
London Blood Tests lists the FarmaIQ Pharmacogenomics Test in its online shop. The product may suit people who want to explore genetic factors in medication response, but the specific panel content and actionable medicines should be checked before purchase.
Because this is a genetics-based test rather than a routine blood profile, follow the kit's stated collection instructions. Where the result relates to a current medicine, arrange a review with the prescriber or a clinician experienced in pharmacogenomics rather than making dose changes yourself.
Frequently asked questions
Can a DNA test tell me which antidepressant will work?
Not reliably. Some gene–drug associations may be informative, but they do not predict the full clinical response.
Does pharmacogenetic testing need to be repeated every year?
Inherited DNA usually does not change. However, medical knowledge and prescribing recommendations can evolve.
Will my GP automatically use a commercial report?
Not necessarily. Clinical utility, laboratory quality, the variants tested and local care pathways all affect whether the findings can guide prescribing.
Can a test diagnose a drug allergy?
A routine pharmacogenetic panel cannot diagnose most drug allergies. Specialist allergy assessment may be required.
Is pharmacogenomics useful for everyone?
Its greatest value is in specific gene–medicine decisions supported by good evidence, not as an automatic screening test for every patient.
The key point
Pharmacogenetic testing UK services can provide useful insight when the gene–medicine relationship is established and a qualified prescriber can act on it. Ask exactly what a panel measures and what decision the result is intended to support.
Medical sources: NICE HTG724 – CYP2C19 and clopidogrel; NICE – overview of CYP2C19 testing after stroke or TIA.
Medical information only. Never change prescription medicines solely because of a consumer genetic report.